GLP1R and type 2 diabetes mellitus: Marquis‐Gravel and Tardif revealed that the use of GLP‐1 receptor agonists in T2DM patients was associated with good cardiovascular outcomes regarding AS risk, and these findings suggest that metformin may have an indirect protective effect against the development of AS by increasing GLP‐1 levels.66